Alimentary Pharmacology & Therapeutics
Cure8 research brief
Why This Matters
People with IBD and coexisting primary sclerosing cholangitis (PSC) are at higher colorectal neoplasia risk and may respond differently to IBD medicines. This meta-analysis compiles available evidence on commonly used advanced therapies to help inform treatment expectations and highlight gaps.
Who Should Pay Attention
Clinicians treating PSC-IBD, gastroenterology researchers, adult patients with PSC-IBD, and patients on biologics or JAK inhibitors.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study synthesised five retrospective case series (n=394) with median follow-up ~18 months. Pooled clinical remission was about 25% at 3 months and ~29% at 6–12 months; corticosteroid-free remission was higher (~45%). Mucosal healing occurred in ~26% overall.
Tofacitinib had a single-study signal for a higher clinical response (~59%) with low adverse events in that report. Overall adverse-event-related discontinuation was ~9%, while ~32% had primary non-response or secondary loss of response. Colorectal neoplasia and colorectal cancer were reported among the pooled patients.
Study limitations and next steps: All included studies were retrospective case series with small samples and heterogeneity in outcomes and follow-up. The authors call for prospective, controlled studies using standardized IBD outcomes in PSC-IBD to better define effectiveness and safety.
Keep In Mind
The review pooled only retrospective case-series with varied methods and small sample sizes; findings should be interpreted cautiously. The structured content provided is an abstract-level synthesis from the published article.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationAlimentary Pharmacology & Therapeutics
AuthorsAmera Elzubeir, Atul Kumar, A. McArdle +4 more
InstitutionUniversity of East Anglia
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedOct 21, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Comparative efficacy and safety of subcutaneous vedolizumab versus other targeted inflammatory bowel therapies in patients with moderate to severe ulcerative colitis: a network meta-analysis update
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...
Patterns and factors associated with dose escalation during maintenance treatment for inflammatory bowel disease: a population-based cohort study.
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...
Immunomodulators and advanced therapies for maintenance of remission in Crohn's disease: systematic review and network meta-analysis.
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...